Biotech RadarJobs updated

COMPANY

Protara Therapeutics

HQ: New York, NY source · protaratx.com ↗ · Mid-Atlantic

Clinical Phase 3

Keywords: oncology rare disease cancer rare diseases Non-muscle Invasive Bladder Cancer Bladder (Urothelial, Transitional Cell) Cancer Non-Muscle Invasive Bladder Carcinoma Lymphatic Malformation Choline Deficiency Liver Injury Intestinal Failure-associated Liver Disease TARA-002

Location: New York, NY · source · Oct 14, 2026

Profile checked Oct 10, 2026

$100.0MRaised (2 yrs)7Trials (company is sponsor)

Timeline

  1. Trial start Phase 3: Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer source ↗
  2. Trial start Phase 2/Phase 3: Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support source ↗
  3. Raise Follow-on offering: $100M (total, as published), announced Dec 9, 2024. Source: SEC filing. source ↗
  4. Trial start Phase 2: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age source ↗
  5. Trial start Phase 2: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer source ↗
  6. Trial start 1: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) source ↗
  7. Trial start 1: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) source ↗
  8. Trial start —: Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $100.0M. Last 2 years.

Clinical trials (lead sponsor) 7

RecordTitlePhaseStatusStartPrimary completion
NCT07480356Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerPhase 3RecruitingMay 29, 20262028-04 (estimated)
NCT05871970Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of AgePhase 2RecruitingOct 18, 20232026-12 (estimated)
NCT05951179Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerPhase 2RecruitingSep 15, 20232031-10 (estimated)
NCT06910943Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral SupportPhase 2/Phase 3RecruitingDec 10, 20252028-03 (estimated)
NCT05085977Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)1CompletedMar 10, 2022Sep 3, 2024 (actual)
NCT05085990Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)1CompletedMay 8, 2023Sep 12, 2024 (actual)
NCT05011370Prevalence of Liver Disease in Patients Dependent on Parenteral NutritionNot listedCompletedAug 23, 2021Jun 29, 2023 (actual)
Feedback